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Octreotide (SMS), a somatostatin analogue, is an es- 
tablished antigrowth peptide, but it does not effectively 
inhibit the growth of insulinoma cells. In order to study 
the mechanisms that underlie this apparent lack of an 
antiproliferative effect on insulinoma tumor cells we 
established the rat insulinoma cell line, RINm5F, in 
culture. Cells in culture were tested by incubation in 
media with and without SMS. To study tritiated [3H]- 
thymidine incorporation into extracted DNA (TTID), 2 
pCi/well of 3H was added for 24 hr, and cells were har- 
vested and assayed for TTID (cpm/pg DNA). Insulin 
(IRI) and intracellular CAMP (cAMPi) were measured 
by RIA. To study the effects of SMS on insulin secre- 
tion, conditioned media were sampled after 24 hr. To 
study the effects of cAMPi, conditioned medium was 
used to extract cAMPi following incubation with SMS 
for 15 min. Increasing concentrations of SMS had no 
significant effect on TTID in the presence of 1% FBS. 
Trypan blue exclusion tests showed >90% viable cells 
throughout all stages of these experiments. There were 
no significant differences in cell numbers and protein 
content in the presence of SMS. There was a significant 
decrease in the secretion of insulin and intracellular 
CAMP levels in response to 50 nMSMS. However, SMS 
significantly inhibited TTID in RINm5F cells follow- 
ing a 4-hr pretreatment with pertussis toxin (PT) 
(23553 + 1747 vs 20635 [cpm/pg DNA] + 1983 [SEMI, 
P < 0.01). We conclude that the inhibition of insulin 
secretion by SMS is associated with an attenuation of 
CAMP formation. However, the effects of SMS on cell 
proliferation appear to be distinct and more complex. 
The unexpected ability of PT to induce the inhibition of 
TTID by SMS suggests that SMS mediates, at least 
some of, its effects on cell proliferation in RINm5F cells 
via a possibly altered G protein or related signal trans- 
ducing mechanism. Further study of the signal trans- 
duction system in RINm5F cells may elucidate the mech- 
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INTRODUCTION 
Somatostatin, a cyclic tetradecapeptide initially iso- 
lated from ovine hypothalamus as an inhibitor of growth 
hormone release, has been localized in many other tis- 
sues [l]. It is a well-established antisecretory and anti- 
proliferative peptide. Sandostatin (octreotide, SMS 
201-995, Sandoz Pharmaceutical Co., East Hanover, 
NJ) is a long-acting, octapeptide analogue of somato- 
statin. It, similarly, has demonstrated antiproliferative 
effects (both in uiuo and in uitro) on a variety of solid 
tumors including breast [2], prostate [3, 41, colon [5], 
pancreatic [6], and small-cell lung carcinoma [ 71, as well 
as, other clonal tumor cells [8,9]. Also, it has been shown 
to inhibit peptide secretion in patients with functioning 
endocrine tumors [lo-121. However, octreotide (SMS) 
does not effectively inhibit the growth of cells in insulin- 
omas, despite it being a well-established antigrowth 
peptide. 
Transmembrane signal (hormone, growth factor, etc.) 
receptors are associated with a class of proteins bound to 
the cytoplasmic side of the cell membrane which bind to 
guanine nucleotides such as guanosine triphosphate 
(GTP) with high affinity [13]. These membrane-bound 
cytoplasmic guanine nucleotide-binding proteins, called 
G proteins [14, 151, are linked to protein synthesis [13, 
161 and are believed to play a role in controlling cell 
proliferation and growth [ 171. 
Somatostatin is known to act via an inhibitory gua- 
nine nucleotide binding protein (Gi) in many cell sys- 
tems [l&-25]. The absence of any demonstrable somato- 
statin-induced antiproliferative effect on insulinoma 
cells suggests that there may be either an altered or a 
different guanine nucleotide subunit protein, or a re- 
lated transduction mechanism in insulinomas. To study 
this further, we established the rat insulinoma cell line, 
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RINm5F, in culture to use as a model for human insulin- 
oma. The RINm5F cell line was originally established 
from an X-ray induced rat insulinoma [ 261 and has been 
shown to store and release immunoreactive insulin [ 271. 
The release of insulin from RINm5F cells is stimulated 
by a variety of secretagogues (amino acids and triose 
glyceraldehyde), but not by glucose [28, 291. 
METHODS 
RINm5F cells were maintained in 75cm2 tissue cul- 
ture flasks at 37°C in 5% CO, in Roswell Park Memorial 
Institute 1640 culture media (RPMI-1640) supple- 
mented with 5% heat-inactivated fetal bovine serum, 2 
mM L-glutamine, 1% penicillin, and 1% streptomycin 
and were allowed to grow to confluence before beginning 
each experimental protocol. In preparation for each ex- 
periment, cells were detached using 0.05% trypsin- 
0.53% mM NaEDTA in Hank’s balanced salt solution 
and subsequently were plated onto 5 wells in 6-well tis- 
sue culture plates and grown in 2 ml medium supple- 
mented with 1% fetal bovine serum X 48 hr. This was 
followed by 2 ml of standard media (RPMI-1640 with 2 
mM L-glutamine, 1% penicillin, and 1% streptomycin) 
supplemented with 0.5% fetal bovine serum X 24 hr. The 
medium was aspirated and 2 ml fresh medium was added 
at the start of all test conditions. The viability of cells 
was tested by trypan blue exclusion tests. These tests 
showed >90% viable cells throughout all stages of these 
experiments. 
Treatment with Pertussis Toxin 
RINm5F cells were pretreated with pertussis toxin 
(PT) (100 rig/ml) for 4 hr. Studies in which RINm5F 
cells were preincubated with concentrations of PT rang- 
ing from 50 to 400 rig/ml produced results that were simi- 
lar to those obtained with 100 rig/ml for a 4-hr pretreat- 
ment. The wells containing PT were aspirated, replaced 
with 2 ml medium, and the respective additive dosages of 
octreotide were used for each test condition. 
Treatment with Octreotide (SMS 201:995) 
Cells were incubated with octreotide (50,500, or 5000 
nM) X 16 hr prior to a 24-hr pulse with tritiated thymi- 
dine. Previous experiments have demonstrated that 
throughout a range of 5 X lop4 M to lo-l5 M octreotide 
50 and 500 nM most consistently produced the maxi- 
mum responses in tritiated thymidine incorporation 
into extracted DNA [30]. 
Tritiated Thymidine Uptake 
Following a 16-hr incubation, 2 &i/well [methyl-3H] - 
thymidine (Amersham) was added to cells. RINm5F 
cells were incubated for 24 hr, then washed with cold 
phosphate-buffered saline. Two milliliters of 6% trichlo- 
roacetic acid was added to each well, and cells were 
scraped and rinsed from tissue culture plates. Cell frag- 
ments were centrifuged ~2 at 1800 rpm for 20 min. The 
supernatant was used to measure the protein content 
and counts in a scintillation counter. The cell pellet was 
treated with 3% perchloric acid (PCA), heated at 95°C 
for 10 min, iced for 20 min, and then centrifuged at 2900 
rpm for 10 min. Supernatant was used to measure DNA 
by direct assay. 
DNA Assay 
Two hundred and fifty microliters of 3% perchloric 
acid was added to assay tubes. DNA standard was pre- 
pared using 0.3 mg/ml DNA (calf thymus, Sigma) in 5 
mM NaOH diluted 1:l in 1 N perchloric acid, heated to 
70°C for 15 min. 
A DNA standard curve was used to estimate unknown 
values. One milliliter of diphenylamine reagent was 
added to a total volume of 500-~1 samples and incubated 
at 30°C for 6-24 hr. Samples were read at 600 nm on a 
spectrophotometer (Hitachi, Model 100-40). Results for 
tritiated thymidine incorporation into extracted DNA 
were calculated and expressed as counts per minute per 
microgram of DNA. 
Insulin 
To study the effects of octreotide on insulin secretion, 
conditioned media were sampled after 24 hr with and 
without octreotide. Replicates ~5 were used in each 
experiment. Results are expressed as mean + 
SEM (N > 3). 
Immunoreactive insulin was measured by using a dou- 
ble-antibody radioimmunoassay with an lz51-porcine in- 
sulin tracer, a rat insulin standard (Novo), a guinea pig 
anti-rat insulin first antibody (Linco Research), and a 
sheep anti-guinea pig gamma globulin-PEG second an- 
tibody. Limit of sensitivity for the assay was 3 pU/ml. 
Interassay and intraassay coefficients of variability were 
3.2 and 1.4%, respectively. 
Cyclic Adenosine Monophosphate (CAMP) 
Intracellular CAMP was measured following incuba- 
tion with octreotide for 15 min. Cold 6% TCA (1 ml) was 
added to wells, and cells were scraped off using a rubber 
policeman. Fragments and TCA were collected and 
placed into tubes (5 wells/tube) and centrifuged at 1800 
rpm for 20 min. The supernatant was washed in 4 X 4 ml 
with diethyl ether (saturated with water), and 200 ml 
from the aqueous layer was assayed for immunoreactive 
CAMP. 
A double-antibody radioimmunoassay using an lz51 
tracer (New England Nuclear), a rabbit anti-CAMP first 
antibody (Vaitukatis, Boston City Hospital), and a 
sheep anti-rabbit IgG second antibody was applied. The 
sample and standards are acetylated prior to assaying 




FIG. 1. The response of cell number in RINm5F cells to various 
doses of octreotide (SMS). RINm5F cells (106) were plated and grown 
as described under Methods. The media was then aspirated. Cells were 
then incubated in test media containing 1% fetal bovine serum for 24 
hr. Cells were then scraped and viable cells as determined by trypan 
blue exclusion rest were counted using hemocytometer. The data are 
representative of five experiments. The vertical lines represent f 
SEM. For experimental details, see Methods. 
FIG. 2. The effect of various doses of octreotide (SMS) on tri- 
tiated thymidine incorporation into extracted DNA from RINm5F 
cells as indicated by cpm/pg DNA on the ordinate-axis. The data are 
representative of three or more experiments. The vertical lines repre- 
sent * SEM. For experimental details, see Methods, and Figure 1. 
for greater sensitivity. Limit of sensitivity is 17.8 fmole/ 
ml. Interassay and intraassay coefficients of variability 
are 5.4 and 1.5%, respectively. 
Statistics 
9, 231. In contrast to these studies, there was no signifi- 
cant inhibition in cell numbers with increasing concen- 
trations of octreotide (50-5000 nM) in the RINm5F cell 
(shown in Fig. 1). Similarly, there were no significant 
changes in protein content observed in RINm5F cells 
incubated in the presence of the same range of dosages of 
octreotide (Table 1). 
Significant differences between treatment groups 
were tested for using the Wilcoxon rank sign test and the 
Student t test. A P value < 0.05 was the criterion used to 
identify a significant difference. 
RESULTS 
To further study the observed lack of effect of octreo- 
tide on RINm5F cell number, we examined the effect of 
octreotide on tritiated thymidine incorporation into the 
extracted DNA of these cells. Increasing concentrations 
of octreotide (50-5000 nM) had no significant effect on 
the extent of tritiated thymidine incorporation into ex- 
tracted DNA (TTID) in RINm5F cells incubated in the 
presence of standard media supplemented with 1% fetal 
bovine serum (shown in Fig. 2). 
Effect of Octreotide on Cell Number and Tritiated 
Thymidine Incorporation 
A number of studies have shown that somatostatin or 
one of its analogues (SMS) inhibit cell proliferation [7- 
Effect of Octreotide on Insulin Secretion and 
Intracellular Cyclic AMP 
Insulin secretion (IRI) and intracellular cyclic AMP 
levels were significantly decreased in RINm5F cells 
TABLE 1 TABLE 2 
Effect of Octreotide (SMS) on Protein Content Effect of Octreotide (SMS) on Insulin Secretion 
and Intracellular Cyclic AMP Formation 
Protein content (pg) 
Test conditions (Reagents) (n = 5) 
Control 108 f 5 
50 nM SMS 102 + 5 
500 nM SMS 110*3 
5000 n&f SMS 120 + 7 
Note. Protein content was measured by the Lowry method [42]. See 
Methods for details. Data are expressed as the mean + SEM from 
triplicate determinations from five experiments. 
Assay Control 
Insulin (pU/ml) 159 f 18 129 4 15* 
Cyclic AMP (fmole/ml) 1233 f 213 1053 f 180* 
Note. Insulin and cyclic AMP were measured by insulin-specific 
and cyclic AMP-specific RIAs, respectively. For details see Methods. 
Data are expressed as the mean + SEM of 9-12 determinations from 
three or more experiments. 
* P i 0.05 from control by Wilcoxon signed rank test. 
SMS (nM) 
SMS 50 nM 
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* p < 0.01 
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FIG. 3. The response of tritiated thymidine incorporation into 
extracted DNA (cpm/ag DNA) in RINm5F cells incubated in stan- 
dard media + 1% fetal bovine serum either alone (control media/con- 
trol) or in control media supplemented with 50 nM octreotide (SMS). 
Both conditions were subjected to either a 4-hr pretreatment with 
pertussis toxin (100 ng/mL) [+PT] or a 4-hr pretreatment without 
pertussis toxin [-PT]. The data are representative of three or more 
experiments. The vertical lines represent f SEM. For experimental 
details. see Methods. 
grown under previously described experimental condi- 
tions in response to SMS (50 nM) (see Table 2). 
Effect of Octreotide on TTID after Pretreatment with 
Pertussis Toxin 
Pretreatment with pertussis toxin is known to disrupt 
the inhibitory alpha subunit of the guanine nucleotide- 
binding regulatory component (GJ by ADP-ribosylation 
and thereby block the inhibitory effect of SMS on the 
adenylate cyclase system. In these experiments, octreo- 
tide alone did not inhibit tritiated thymidine incorpora- 
tion into extracted DNA; however, octreotide signifi- 
cantly inhibited tritiated thymidine incorporation into 
extracted DNA in RINm5F cells pretreated with pertus- 
sis toxin (100 rig/ml/4 hr) (23553 + 1747 vs 20635 [cpm/ 
pg DNA] + 1983 [SEMI, P < 0.01) (shown in Fig. 3). 
Similar results were observed even after pretreatment 
with 400 rig/ml/4 hr of pertussis toxin (data not shown). 
In addition, octreotide also inhibited insulin secretion 
into condition media from 47 f 4.0 to 40 & 4.2 (pU/ml * 
SEM) in RINm5F cells pretreated with 50 rig/ml of per- 
tussis toxin. 
DISCUSSION 
Somatostatin or its analogue is known to be a potent 
antisecretory and antigrowth peptide [31]. However, the 
exact mechanism(s) for its antigrowth effects are un- 
known. There are several fundamental mechanisms by 
which cell growth in endocrine cells may become abnor- 
mal. These mechanisms include abnormalities of growth 
factor production, abnormalities of growth factor recep- 
tors, reduced production of growth-inhibitory regulatory 
factors, or disturbances of post-receptor signal trans- 
duction [32]. Somatostatin may play a role in one or 
more of these fundamental mechanisms controlling ab- 
normal (neoplastic) growth in any given cell. 
Somatostatin was initially isolated based on its ability 
to inhibit growth hormone secretion from rat anterior 
pituitary cells in culture [l]. Subsequently, it has been 
shown to inhibit the secretion of several other hormones 
by pituitary cells in culture [33]. Furthermore, it has 
been shown that somatostatin inhibits such hormonal 
secretion by attenuating the formation of intracellular 
cyclic AMP [34, 351. Our data demonstrating that oc- 
treotide inhibits insulin secretion and intracellular cy- 
clic AMP levels in RINm5F cells are consistent with 
these reported observations. 
Human studies using octreotide in the treatment of 
patients with malignant insulinomas have shown that 
octreotide does not reduce the size or inhibit the growth 
of the tumor, but that it does reduce the levels of circu- 
lating insulin (IRI) in such patients [36-381. Our in vitro 
studies using a rat insulinoma cell line, RINm5F, also 
showed that increasing concentrations of octreotide did 
not reduce or inhibit the proliferation of cells, but it did 
reduce the levels of immunoreactive insulin secreted 
into the conditioned media (see Figs. 1 and 2, Table 2). 
In addition, we did not observe any significant changes 
in the protein content of these cells following treatment 
with octreotide. The parallel patterns of response of 
RINm5F cells in culture to those observed for human 
insulinomas suggest that our experimental model using 
RINm5F cells in vitro is a functional and useful model 
with which to investigate the mechanisms of peptide ac- 
tion in insulinomas. 
Pertussis toxin is known to ADP-ribosylate the inhibi- 
tory alpha subunit of the membrane-bound guanine nu- 
cleotide binding protein, Gi. Somatostatin is known to 
mediate several of its postreceptor effects via the mem- 
brane-bound inhibitory subunit of guanine nucleotide 
binding protein (Gi). Furthermore, it has been shown 
that the inhibitory effects of somatostatin can be 
blocked by pretreatment with pertussis toxin [18, 23, 
24, 391. 
In these experiments, pertussis toxin pretreatment 
followed by treatment with octreotide resulted in a sig- 
nificant inhibition of tritiated thymidine incorporation 
into the extracted DNA of RINm5F cells. The mecha- 
nism for this net inhibitory effect of octreotide in 
RINm5F cells only after pretreatment with pertussis 
toxin is unclear. It is possible that octreotide exerts both 
stimulatory and inhibitory effects on cell proliferation in 
RINm5F cells and that the stimulatory effects are per- 
tussis toxin-sensitive. Alternatively, Gi in the RINm5F 
cell may be altered, expressed differently, or associated 
with an abnormal or a different signal transducting 
mechanism in these cells. Consequently, pertussis toxin 
may exert a net activation of Gi in the RINm5F cell. 
Alteration of G, in disease states is not without prece- 
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dent; for example, it has been shown that in patients 
with non-insulin-dependent diabetes, Gi expression is 
altered [40]. The fact that pretreatment of RINm5F 
cells with pertussis toxin did not significantly alter 
(block) the inhibitory action of octreotide on insulin se- 
cretion (data described under Results) further supports 
the possibility that Gi may be altered or expressed differ- 
ently in RINm5F cells. The observation that pretreat- 
ment of RINm5F cells with pertussis toxin significantly 
altered the response of tritiated thymidine incorpora- 
tion into DNA in these experiments further highlights 
the probability that the mechanisms mediating peptide 
secretion may be distinct from those mechanisms me- 
diating cell proliferation. Recently reported findings on 
the existence of several distinct clones of somatostatin 
receptors in several tissues with apparent distinct cell 
effecters are consistent with this probability [41]. 
In conclusion, we have established a viable model to 
study the mechanisms of action of somatostatin in insu- 
linomas. We have shown that there appears to be two 
distinct mechanisms of action of somatostatin in 
RINm5F cells. It appears that octreotide exerts its inhib- 
itory action on peptide secretion by inhibiting or atten- 
uating cyclic AMP formation, whereas its antiprolifera- 
tive action appears to be related to either the net activa- 
tion of G,, or via an altered or different G protein 
mechanism. Peptide receptors regulate the adenylyl cy- 
clase system and related cell effector systems via G pro- 
teins, as well as second messenger systems that include 
cyclic AMP. Further study of the signal transduction 
system in RINm5F cells may elucidate the apparently 
distinct mechanisms of peptide secretion and tumor cell 









Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, 
J., and Guillemin, R. Hypothalamic polypeptide that inhibits the 
secretion of immunoreactive pituitary growth hormone. Science 
179:77,1973. 
Rose, D. P., Gottardis, M., and Noonan, J. J. Rat mammary carci- 
noma regressions during suppression of serum growth hormone 
and prolactin. Anticancer Res. 3: 323, 1983. 
Schally, A. V., ComaruSchally, A. M., and Redding, T. W. Anti- 
tumor effects of analogs of hypothalamic hormones in endocrine- 
dependent cancers. Proc. Sot. Exp. Biol. Med. 1'75: 259,1984. 
Murphy, W. A., Lance, V. A., Moreau, S., Moreau, J-P, and Coy, 
D. H. Inhibition of rat prostate tumor growth by an octapeptide 
analog of somatostatin. Life Sci. 40: 2515, 1987. 
Smith, J. P., and Solomon, T. E. Effects of gastrin, proglumide, 
and somatostatin on growth of human colon cancer. Gustroenter- 
ology 95: 1541, 1988. 
Upp, J. R. Jr, Olson, D., Poston, G. J., Alexander, R. W., Town- 
send, C. M. Jr, and Thompson, J. C. Inhibition of growth of two 
human pancreatic adenocarcinomas in vivo by somatostatin an- 
alog SMS 201-995. Am. J. Surg. 155: 29, 1988. 
Taylor, J. E., Bogden, A. E., Moreau, J-P, et al. In vitro and in 
vivo inhibition of human small cell lung carcinoma (NCI-H69) 





















Viguerie, N., Tahiri-Jouti, N., Ayral, A. M., Cambillau, C., Sce- 
mama, J. I,., Bastie, M. J., Knuhtsen, S., Esteve, J. P., Pradayrol, 
L., Susini, C., and Vaysse, N. Direct inhibitory effects of a so- 
matostatin analog, SMS 201-995, on AR4-2J cell proliferation 
via pertussis toxin-sensitive guanosine triphosphate-binding 
protein-independent mechanism. Endocrinology 124: 1017, 
1989. 
Pelicci, G., Pagliacci, M. C., Lanfrancone, L., Pelicci, P. G., Grig- 
nani, F., and Nicoletti, I. Inhibitory effect of the somatostatin 
analog octreotide on rat pituitary tumor cell (GH3) proliferation 
in vitro. J. Endocrinol. Znuest. 13: 657, 1990. 
O’Dorisio, T. M., Osei, K., and Falko, J. M. Effects of somato- 
statin (SMS) analog (201-995) on gastrin releasing peptide 
(GRP) and pancreatic polypeptide (PP) during provocative test- 
ing in a benign insulinoma. Clin. Res. 33: 877A, 1985. 
Osei, K., and O’Dorisio, T. M. Malignant insulinoma: Effects of a 
somatostatin analog (compound 201-995) on serum glucose, 
growth, and gastro-entero-pancreatic hormones. Ann. Intern. 
Med. 103:223,1985. 
Delemarre-van De Waal, H. A., Veldkamp, E. J. M., and 
Schrander-Stumpel, C. T. R. M. Long-term treatment of an in- 
fant with nesidioblastosis using a somatostatin analogue. N. 
Engl. J. Med. 316: 222, 1987. 
Hughes, S. M. Are guanine nucleotide binding proteins a distinct 
class of regulatory proteins? FEBS Lett. 164(l): 1, 1983. 
Gilman, A. G. G proteins: Transducers of receptor-generated sig- 
nals. Annu. Rev. Biochem. 56: 615, 1987. 
Stryer, L., and Bourne, H. R. G proteins: A family of signal trans- 
ducers. Annu. Rev. Cell Biol. 2: 391, 1986. 
Spiegel, A. M., Gierschik, P., Levine, M. A., and Downs, R. W., 
Jr. Clinical implications of guanine nucleotide-binding proteins 
as receptor-effector couplers. N. Engl. J. Med. 312: 26, 1985. 
Murayama, T., and Ui, M. Possible involvement of a GTP-bind- 
ing protein, the substrate of islet-activating protein, in receptor- 
mediated signaling responsible for cell proliferation. J. Biol. 
Chem. 262: 12463, 1987. 
Reisine, T., Zhang, Y. L., and Sekura, R. Pertussis toxin treat- 
ment blocks the inhibition of somatostatin and increases the 
stimulation by forskolin of cyclic AMP accumulation and adren- 
ocorticotropin secretion from mouse anterior pituitary tumor 
cells. J. Pharmacol. Exp. Ther. 232: 275, 1985. 
Yajima, Y., Akita, T., and Saito, T. Pertussis toxin blocks the 
inhibitory effects of somatostatin on CAMP-dependent vasoac- 
tive intestinal peptide and CAMP-independent thyrotropin re- 
leasing hormone-stimulated prolactin secretion of GH3 cells. J. 
Biol. Chem. 261(6): 2684, 1986. 
Jacobs, K. H., Aktories, D., and Schultz, G. A nucleotide regula- 
tory site for somatostatin inhibition of adenylate cyclase in S49 
lymphoma cells. Nature 303: 177, 1983. 
Batzri, S. Direct action of somatostatin on dispensed mucosal 
cells from guinea-pig stomach. Biochim. Biophy. Acta. 677: 521, 
1981. 
Soll, A. H., Amirian, D. A., Thomas, L. P., Reedy, T. J., and 
Elashoff, J. D. Gastrin receptors on isolated canine parietal cells. 
J. Clin. Znuest. 73(5): 1434, 1984. 
Raper, S., Kothary, P. C., and Kokudo, N. Somatostatin-14 
blocks the hepatotrophic effects of insulin in the rat. J. Surg. 
Res. 50(4): 386, 1991. 
Park, J., Chiba, T., andyamada, T. Mechanisms for direct inhibi- 
tion of canine gastric parietal cells by somatostatin. J. Biol. 
Chem. 262(29): 14190,1987. 
Susini, C., Bailey, A., Szecowka, J., and Williams, J. A. Charac- 
terization of covalently cross-linked pancreatic somatostatin re- 
ceptors. J. Biol. Chem. 261(35):16738,1984. 
Gazdar, A. F., Chick, W. L., Oie, H. K., Sims, H. L.,etal. Continu- 










ous, clonal, insulin- and somatostatin-secreting cell line estab- Inhibition of GHl rat pituitary tumor cell adenylyl cyclase activ- 
lished from a transplantable rat islet cell tumor. hoc. N&Z. Acad. ity by somatostatin. J. Cyclic Ndeotide Res. 4(6): 453, 1978. 
Sci. USA 77: 3519,198O. 36. Long, R. G., Barnes, A. J., Adrian, T. E., Mallinson, C. N., 
Oie, H. K., Gazdar, A. F., Minna, J. D., et al. Clonal analysis of Brown, M. R., Vale, W., Rivier, J. E., Christofides, N. D., and 
insulin and somatostatin secretion and L-dopa decarboxylase Bloom, S. R. Suppression of pancreatic endocrine tumour secre- 
expression by a rat islet cell tumor. Endocrinology 112: 1070, tion by long-acting somatostatin analogue. Lancet 2: 764, 1979. 
1983. 37. Kvols, L. K., Buck, M., Moertel, C. G., Schutt, A. J., Rubin, J., 
Praz, G. A., Galban, P. A., Wollheim, P. A., et al. Regulation of O’Connell, M. J., and Hahn, R. G. Treatment of metastatic islet 
immunoreactive-insulin release from a rat cell line (RINm5F). cell carcinoma with a somatostatin analogue (SMS 201-995). 
Biochem. J. 210:345,1983. Am. Intern. Med. 107(2):162,1987. 
Halban, P. A., Praz, G. A., and Wollheim, C. B. Abnormal glu- 38. 
case metabolism accompanies failure of glucose to stimulate in- 
sulin release from a rat pancreatic cell line (RINm5F). Biochem. 
J. 212: 439,1983. 
McLeod, M. K., Fukuuchi, A., Warnock, M., Tutera, A. M., and 
Vinik, A. I. Stimulative effects of somatostatin analogue (octreo- 39. 
tide) on cell proliferation in rat insulinoma, RINm5F, cells. Surg. 
Forum 42: 133, 1991. 
Schally, A. V. Oncological applications of somatostatin ana- 46. 
logues. Cancer Res. 48: 6977, 1988. 
Steel, C. M. Peptide regulatory factors and malignancy. Lancet 
2(8653): 30,1989. 
Dorflinger, L. J., and Schonbrunn, A. Somatostatin inhibits va- 
soactive intestinal peptide-stimulated cyclic adenosine mono- 
phosphate accumulation in GH pituitary cells. Endocrinology 
41. 
113:1541,1983. 
Schrezenmeir, J., Plewe, G., Sturmer, W., Kahaly, G., Opper- 
man, D., Krause, U., Del Pozo, E., Kasper, H., and Beyer, J. 
Treatment of APUDomas with the long-acting somatostatin an- 
alog SMS 201-995 investigations of therapeutic use and digestive 
side effects. Scar&. J. Gastroenterol. 21(S119): 223, 1986. 
Katada, T., Bokoch, G. M., Northup, J. K., Ui, M., and Gilman, 
A. G. The inhibitory guanine nucleotide-binding regulatory com- 
ponent of adenylate cyclase. J. Biol. Chem. 259: 3568, 1984. 
Livingstone, C., McLellan, A. R., McGregor, M. A., Wilson, A., 
Connell, J. M., Small, M., Milligan, G., Paterson, K. R., and 
Houslay, M. D. Altered G-protein expression and adenylate cy- 
clase activity in platelets of non-insulin-dependent diabetic 
(NIDDM) male subjects. Biochim. Biophys. Acta 1096: 127, 
1991. 
Schofield, J. G., Mira-Moser, F., Schorderet, M., and Orci, L. 
Somatostatin inhibition of rat growth hormone release in vitro 
in the presence of BaCl, or 3-isobutyl-1-methylxanthine. FEBS 42 
Lett. 46: 171, 1974. 
Heindel, J. J., Williams, E., Robison, G. A., and Strada, S. J. 
Yamada, Y., Post, S. R., Wang, K., Tager, H. S., Bell, G. I., and 
Seino, S. Cloning and functional characterization of a family of 
human and mouse somatostatin receptors expressed in brain, 
gastrointestinal tract, and kidney. Proc. Natl. Acad. Sci. USA 
89: 251, 1992. 
Lowry, 0. H., Rosenbrough, N. J., Farr, A. L., and Randall, R. J. 
Protein measurement with the folin phenol reagent. J. Biol. 
Chem. 193:265,1951. 
